Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 110,649

Document Document Title
WO/2015/159112A1
The invention relates to a compound having SSAO/VAP-1 inhibitor activity for use in the treatment of hyperalgesia and allodynia implicated in traumatic neuropathy or neurogenic inflammation. Accordingly, the invention relates to a compou...  
WO/2015/155451A1
Combination between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8- dihydro-3H-[l,3] oxazino[6,5-g][l,2,3]benzotriazine-4,9-dione of formula (I) or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcho...  
WO/2015/157182A1
The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D,...  
WO/2015/157451A1
The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a ...  
WO/2015/157117A3
The present invention provides methods for assessing whether a subject is at risk of developing a neurological disorder, diagnosing or confirming whether a subject is afflicted with a neurological disorder, assessing whether PD has progr...  
WO/2015/157738A1
Provided herein are methods and compositions for effective pain treatment, which also reduce or eliminate adverse effects.  
WO/2015/157212A1
This application relates to a stable liquid aqueous formulations comprising at least about 10 mg/ml of apomorphine hydrochloride hemihydrate (apomorphine HQ), which are substantially free of antioxidant agents, such as sodium metabisulfi...  
WO/2015/154721A1
An isoacteoside derivative and preparation method and use thereof; the isoacteoside derivative has a structure of formula (I): R1 and R2 are independently selected from hydrogen, halogen, hydroxyl and alkoxy oxyl; R3 and R4 are independe...  
WO/2015/155544A1
There is described a volatile form of an NSAID, and derivatives thereof, for use in the treatment of a neurological disorder. There is also described a method of treatment of a neurological disorder which comprises administering to a mam...  
WO/2015/157509A1
The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated disease...  
WO/2015/154691A1
A composition for use in the treatment of brain injury and/or cerebral stoke, comprise an effective amount of Astragalus membranaceus extract and pharmaceutically acceptable carrier, excipients or salts. The Astragalus membranaceus extra...  
WO/2015/157559A3
Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions...  
WO/2015/155566A1
The present invention relates to compounds of formula I, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N- oxides thereof, and processes for their preparation. ...  
WO/2015/155694A1
The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues ...  
WO/2015/157514A1
The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention provides methods and compositions useful for treating Parkinson's disease. In a specific embodiment, a method for reducing...  
WO/2015/154673A1
The invention relates a pharmaceutical composition comprising (i) prodrugs of NEP inhibitors, (ii) mutual prodrugs of angiotensin receptor antagonist and a NEP inhibitor, (iii) a combination of an angiotensin receptor antagonist prodrug ...  
WO/2015/155153A1
The present invention provides a new synthetic process for the production of 1 -(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2,4-dimethylphenyl...  
WO/2015/155306A1
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by TRPA1 channel inhibition or an...  
WO/2015/154141A1
The present invention provides a method for delivering a P methysticum extract to an animal in need thereof, the method comprising the steps of: (i) administering the P methysticum extract orally to the animal, and (ii) administering an ...  
WO/2015/155218A1
Selective inhibitor of c-Fos and their antiproliferative properties The invention relates to selective inhibitor of c-Fos for use in the prevention and/or treatment of cancers and restenosis.  
WO/2015/156421A1
The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or phylactic agent for diseases induced by production, secr...  
WO/2015/154192A1
Compositions comprising a flavan-3-ol, a flavonoid, and a fatty acid have been demonstrated to mitigate the oxidative damage arising from mitochondrial dysfunction. In preferred embodiments, the composition comprises epicatechin, quercet...  
WO/2015/154630A1
Disclosed is a series of analogues of 4H-pyrazolo[1,5-α]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP i...  
WO/2015/157187A1
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...  
WO/2015/154191A1
Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ...  
WO/2015/155207A1
The present invention relates to a pharmaceutical composition for use in a method for treatment or prevention of a-synucleinopathies wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a ma...  
WO/2015/152311A1
 The problem of the present invention is to provide a melatonin secretion regulator capable of regulating melatonin secretion in vivo; this problem is solved by providing a melatonin secretion regulator containing ornithine or a salt t...  
WO/2015/153971A1
Methods of treating a subject with a neurodegenerative disease or central nervous system disorder; methods of reducing, delaying, or preventing one or more symptoms of a neurodegenerative disease or central nervous system disorder in a s...  
WO/2015/150097A1
Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different a...  
WO/2015/150476A1
The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.  
WO/2015/152367A1
Provided is a novel compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or pharmaceutically acceptable salt thereof exhibits orexin (OX) receptor antagonistic action, and thus is useful for the...  
WO/2015/150612A1
The invention relates to a family of differently substituted isatins that exhibit activity inhibiting the protein kinase with leucine-rich repeats (LRRK2), such that they are useful in the treatment of diseases mediated by said enzyme, s...  
WO/2015/150440A1
The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2015/153800A3
Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and condit...  
WO/2015/152688A1
The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, the pharmaceutical composition comprising a graphene nanostructure as an active ingredient.  
WO/2015/150254A1
The present invention provides halogenated quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2015/150957A1
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Co...  
WO/2015/150383A1
The present invention relates to glycolic acid or a pharmaceutically acceptable salt or ester thereof, and/or D-lactic acid or a pharmaceutically acceptable salt or ester thereof for use in the treatment of a neurodegenerative disease wh...  
WO/2015/153720A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/153658A2  
WO/2015/152253A1
The present invention provides a compound that has a strong regulatory effect for an α7 nicotinic acetylcholine receptor (α7 nAChR), and is useful as a therapeutic drug for diseases associated with cholinergicity of the central nervous...  
WO/2015/152368A1
Provided is a novel compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or pharmaceutically acceptable salt thereof exhibits orexin (OX) receptor antagonistic action, and thus is useful for the...  
WO/2015/153709A1
The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)ph enyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyc lopenta[d]pyrimidine-2,4 -diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A...  
WO/2015/150934A1
Peptide system comprising at least one peptide blocking the presynaptic release of glutamate, said peptide having sequence SEQ ID NO 5: GRKKRRQRRRPPIEQSIEQEEGLNRS; and/or sequence SEQ ID NO 8: GRKKRRQRRRPPMSEYNATQSDYRER for use in treati...  
WO/2015/150294A1
The present invention relates to solid pharmaceutical compositions comprising biopterin derivatives as well as methods for obtaining such solid pharmaceutical compositions. The compositions contain the active ingredient and phosphate sal...  
WO/2015/150839A1
A compound of Formula I: R1 -L1 -C(A)(A') - CH2, - L2-R2 or a pharmaceutically acceptable salt thereof, for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spect...  
WO/2015/152254A1
The present invention provides a compound that has a strong α7 nicotinic acetylcholine receptor (α7 nAChR)-regulating effect and is useful as a therapeutic drug for diseases associated with cholinergicity of the central nervous system ...  
WO/2015/152813A1
The present invention relates to a novel gene expression system comprising : a) a first nucleotide sequence encoding a fusion polypeptide of: a1) a destabilizing domain (DD) based on DHFR, and a2) a GTPcyclohydrolase 1 (GCH1) polypeptide...  
WO/2015/144576A1
The present invention relates to the use of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol -2- one or a physiologically acceptable salt thereof in a method for treatment and/or prevention of one or more epileptic disorders ...  
WO/2015/144290A8
The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or d...  

Matches 651 - 700 out of 110,649